Peptides such as Thymosin Alpha-1 have been developed for the past twenty years. After early research studies suggested favorable results, Thymosin Alpha-1 has been suggested to act as an ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

Hims & Hers Health, Inc. (NYSE:HIMS) shares stumbled Friday afternoon. The company, the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...

Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s lon ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Fashion girlies celebrate this occurrence as well, because Hailey Bieber will undoubtedly churn out an enviable look at the ...